康诺亚_中国免疫诊断蓬勃发展中的关键参与者

Keymed Bioscience (2162.HK) A key player in China's booming immunology November 2025 A well-established immunology biotech with upside potential from its pipeline Stapokibart as a validation for the company's R&D/regulatory capabilities: Upside from CM512 (TSLP/IL-13 bispecific) with breakthrough potential: Early-stage development to enrich immunology pipeline with diversified modalities Unlock global potential of oncology pipeline through partnership Honglin Yan Goldman Sachs (Asia) LLC +852-2978-6666 hong ...